Analyst Reco. Biogen Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 10:54:08 2024-04-26 am EDT			5-day change	1st Jan Change
206.1 ^USD	+1.82%		+6.44%	-20.05%

Apr. 25	Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA	CI
Apr. 25	Goldman Sachs Adjusts Biogen Price Target to $340 From $393	MT

Goldman Sachs Adjusts Biogen Price Target to $340 From $393	Apr. 25	MT
Canaccord Genuity Adjusts Price Target on Biogen to $308 From $305	Apr. 25	MT
Barclays Adjusts Price Target on Biogen to $200 From $215	Apr. 25	MT
HC Wainwright Adjusts Biogen's Price Target to $300 From $325	Apr. 25	MT
Wedbush Adjusts Price Target on Biogen to $215 From $213	Apr. 25	MT
Morgan Stanley Cuts Biogen's Price Target to $331 From $339	Apr. 24	MT
Piper Sandler Raises Biogen's Price Target to $335 From $325	Apr. 24	MT
RBC Lowers Biogen's Price Target to $317 From $326	Apr. 24	MT
Needham Adjusts Price Target on Biogen to $294 From $300	Apr. 19	MT
BMO Capital Adjusts Price Target on Biogen to $260 From $285, Outperform Rating Kept	Apr. 19	MT
Oppenheimer Adjusts Biogen Price Target to $270 From $290	Apr. 19	MT
UBS Adjusts Biogen's Price Target to $214 From $250, Maintains Neutral Rating	Apr. 17	MT
Wedbush Cuts Biogen's Price Target to $213 From $245	Apr. 17	MT
Argus Adjusts Biogen's Price Target to $240 From $315	Apr. 15	MT
Goldman Sachs Cuts Biogen's Price Target to $393 From $400	Apr. 15	MT
JPMorgan Cuts Biogen's Price Target to $240 From $270, Maintains Neutral Rating	Apr. 11	MT
Morgan Stanley Trims Price Target on Biogen to $339 From $346, Keeps Overweight Rating	Apr. 09	MT
Barclays Cuts Price Target on Biogen to $215 From $230, Maintains Equalweight Rating	Apr. 04	MT
BIOGEN : Jefferies confirms its Buy rating on the stock	Mar. 19	CF
Canaccord Genuity Adjusts Price Target on Biogen to $305 From $310, Keeps Buy Rating	Feb. 20	MT

No results for this search